Matthew Roe, MD

Matthew Roe, MD

Professor of Medicine

Duke Clinical Research Institute

Duke University School of Medicine

Durham, NC

Related Videos

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy? Video

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

Do you have any safety concerns about driving LDL-C levels to less than 50 mg/dL with PCSK9 inhibitors? Video

Do you have any safety concerns about driving LDL-C levels to less than 50 mg/dL with PCSK9 inhibitors?

How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL? Video

How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials? Video

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial? Video

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?